Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan

American Journal of Kidney Diseases

Volumn 60, Issue 2, 2012, Pages 262-271

  Komaba, Hirotaka ^a,b   Moriwaki, Kensuke ^c,d   Goto, Shunsuke ^b   Yamada, Shunsuke ^e   Taniguchi, Masatomo ^e   Kakuta, Takatoshi ^a   Kamae, Isao ^d,f   Fukagawa, Masafumi ^a,b  

^a TOKAI UNIVERSITY   (Japan)

^b KOBE UNIVERSITY   (Japan)

^c NIIGATA UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

^f KEIO UNIVERSITY   (Japan)

Author keywords

Cinacalcet hydrochloride; cost effectiveness; hemodialysis; secondary hyperparathyroidism

Indexed keywords

CINACALCET; PARATHYROID HORMONE;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DISEASE SEVERITY; HEMODIALYSIS PATIENT; HUMAN; JAPAN; PARATHYROIDECTOMY; QUALITY ADJUSTED LIFE YEAR; SECONDARY HYPERPARATHYROIDISM; SIMULATION; TREATMENT OUTCOME;

AGED; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MARKOV CHAINS; MIDDLE AGED; MONTE CARLO METHOD; NAPHTHALENES; PARATHYROIDECTOMY; QUALITY-ADJUSTED LIFE YEARS; RENAL DIALYSIS;

EID: 84863990017     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2011.12.034     Document Type: Article

References (62)

1. US Renal Data System USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States Am J Kidney Dis 57 1 2011 e1 e526 (suppl 1)
2. S. Fukuhara, C. Yamazaki, Y. Hayashino The organization and financing of end-stage renal disease treatment in Japan Int J Health Care Finance Econ 7 2-3 2007 217 231
3. T.B. Drüeke Cell biology of parathyroid gland hyperplasia in chronic renal failure J Am Soc Nephrol 11 6 2000 1141 1152
4. M. Fukagawa, S. Nakanishi, J.J. Kazama Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease Kidney Int Suppl 102 2006 S3 S7
5. H. Komaba, K. Moriwaki, I. Kamae, M. Fukagawa Towards cost-effective strategies for treatment of chronic kidney disease-mineral and bone disorder in Japan Ther Apher Dial 13 suppl 1 2009 S28 S35
6. K.A. Hruska, S.L. Teitelbaum Renal osteodystrophy N Engl J Med 333 3 1995 166 174
7. G.A. Block, P.S. Klassen, J.M. Lazarus, N. Ofsthun, E.G. Lowrie, G.M. Chertow Mineral metabolism, mortality, and morbidity in maintenance hemodialysis J Am Soc Nephrol 15 8 2004 2208 2218
8. E.W. Young, J.M. Albert, S. Satayathum Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study Kidney Int 67 3 2005 1179 1187
9. Y. Slinin, R.N. Foley, A.J. Collins Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS Waves 1, 3, and 4 Study J Am Soc Nephrol 16 6 2005 1788 1793
10. K. Kalantar-Zadeh, N. Kuwae, D.L. Regidor Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients Kidney Int 70 4 2006 771 780
11. N. Kimata, J.M. Albert, T. Akiba Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan Dialysis Outcomes and Practice Patterns Study Hemodial Int 11 3 2007 340 348
12. S. Nakai, T. Akiba, J. Kazama Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan Ther Apher Dial 12 1 2008 49 54
13. F. Tentori, M.J. Blayney, J.M. Albert Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS) Am J Kidney Dis 52 3 2008 519 530
14. J.D. Punch, N.W. Thompson, R.M. Merion Subtotal parathyroidectomy in dialysis-dependent and post-renal transplant patients A 25-year single-center experience Arch Surg 130 5 1995 538 543
15. S. Stracke, P.M. Jehle, D. Sturm Clinical course after total parathyroidectomy without autotransplantation in patients with end-stage renal failure Am J Kidney Dis 33 2 1999 304 311
16. F.F. Chou, J.C. Ho, S.C. Huang, S.M. Sheen-Chen A study on pruritus after parathyroidectomy for secondary hyperparathyroidism J Am Coll Surg 190 1 2000 65 70
17. Y. Tominaga, K. Uchida, T. Haba More than 1,000 cases of total parathyroidectomy with forearm autograft for renal hyperparathyroidism Am J Kidney Dis 38 4 2001 S168 S171 (suppl 1)
18. B. Kestenbaum, D.L. Andress, S.M. Schwartz Survival following parathyroidectomy among United States dialysis patients Kidney Int 66 5 2004 2010 2016
19. K.D. Rudser, I.H. de Boer, A. Dooley, B. Young, B. Kestenbaum Fracture risk after parathyroidectomy among chronic hemodialysis patients J Am Soc Nephrol 18 8 2007 2401 2407
20. G.A. Block, K.J. Martin, A.L.M. de Francisco Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis N Engl J Med 350 15 2004 1516 1525
21. J.S. Lindberg, B. Culleton, G. Wong Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized double-blind, multicenter study J Am Soc Nephrol 16 3 2005 800 807
22. M. Fukagawa, S. Yumita, T. Akizawa Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients Nephrol Dial Transplant 23 1 2008 328 335
23. T. Akiba, T. Akizawa, Y. Tsukamoto, E. Uchida, M. Iwasaki, S. Koshikawa Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism Ther Apher Dial 12 2 2008 117 125
24. T. Shigematsu, T. Akizawa, E. Uchida Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism Am J Nephrol 29 3 2009 230 236
25. H. Komaba, S. Nakanishi, A. Fujimori Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism Clin J Am Soc Nephrol 5 12 2010 2305 2314
26. R. Narayan, R.M. Perkins, E.P. Berbano Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis Am J Kidney Dis 49 6 2007 801 813
27. S.M. Sprague, P. Evenepoel, M.P. Curzi Simultaneous control of PTH and CaxP is sustained over three years of treatment with cinacalcet HCl Clin J Am Soc Nephrol 4 9 2009 1465 1476
28. M.F. Drummond, A. McGuire Economic Evaluation in Health Care: Merging Theory With Practice New York, NY: Oxford University Press 2001
29. S. Nakai, K. Suzuki, I. Masakane Overview of regular dialysis treatment in Japan (as of 31 December 2008) Ther Apher Dial 14 6 2010 505 540
30. M. Taniguchi, S. Yamada, K. Tsuruya, M. Iida, H. Hirakata Bone metabolism and risk of death and cardiovascular disease (CVD) in uremic patients: a prospective cohort study in Japan Kidney Metab Bone Dis 22 4 2009 361 362
31. S. Nakai, T. Shinzato, T. Sanaka The current state of chronic dialysis treatment in Japan J Jpn Soc Dial Ther 35 7 2002 1155 1184
32. M. Jadoul, J.M. Albert, T. Akiba Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study Kidney Int 70 7 2006 1358 1366
33. M. Coco, H. Rush Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone Am J Kidney Dis 36 6 2000 1115 1121
34. M.D. Danese, J. Kim, Q.V. Doan PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis Am J Kidney Dis 47 1 2006 149 156
35. Y. Tominaga, A. Katayama, T. Sato Re-operation is frequently required when parathyroid glands remain after initial parathyroidectomy for advanced secondary hyperparathyroidism in uraemic patients Nephrol Dial Transplant 18 suppl 3 2003 iii65 iii70
36. Jihou National Health Insurance Price List [in Japanese] 2010 Jihou Press Tokyo, Japan
37. M. Fukagawa, H. Komaba, Y. Onishi, S. Fukuhara, T. Akizawa, K. Kurokawa Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: baseline data from the MBD-5D Am J Nephrol 33 5 2011 427 437
38. T. Akizawa, R. Kido, M. Fukagawa Decreases in PTH in hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns in the MBD-5D Study Clin J Am Soc Nephrol 6 9 2011 2280 2288
39. DPC tennsuu hayami-hyo [Diagnostic Procedure Combination fee schedule in Japan] 2010 Igaku-tushinsha Tokyo, Japan
40. I. Saito, M. Kobayashi, Y. Matsushita, A. Mori, K. Kawasugi, T. Saruta Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model Hypertens Res 31 7 2008 1373 1383
41. A. Kondo, B.K. Zierler, Y. Isokawa, H. Hagino, Y. Ito Comparison of outcomes and costs after hip fracture surgery in three hospitals that have different care systems in Japan Health Policy 91 2 2009 204 210
42. H. Sugisaki, Y. Ohta, S. Ohira Cost of dialysis treatment in Japan: Eleventh Annual Report of the Japanese Association of Dialysis Physicians, 2007 [in Japanese] J Jpn Assoc Dial Physicians 23 1 2008 49 94
43. S. Fukuhara, A.A. Lopes, J.L. Bragg-Gresham Health-related quality of life among dialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study Kidney Int 64 5 2003 1903 1910
44. O. Inada, S. Nishimura, M. Matsushima, Y. Seino, K. Tsuda The direct medical costs and the quality of life in patients with artificial dialysis and type 2 diabetes [in Japanese] J Japan Diabetic Soc 50 1 2007 1 8
45. R. Ara, J. Brazier Predicting the Short Form-6D preference-based index using the eight mean Short Form-36 health dimension scores: estimating preference-based health-related utilities when patient level data are not available Value Health 12 2 2009 346 353
46. R. Garside, M. Pitt, R. Anderson, S. Mealing, R. D'Souza, K. Stein The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective Nephrol Dial Transplant 22 5 2007 1428 1436
47. E.M. Mahoney, C.T. Jurkovitz, H. Chu Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-CT-segment elevation myocardial infarction JAMA 288 15 2002 1851 1858
48. A.S. Pickard, J.A. Johnson, D.H. Feeny Responsiveness of generic health-related quality of life measures in stroke Qual Life Res 14 1 2005 207 219
49. T. Hisashige, T. Katayama, T. Ishibashi Estimation of the quality of the life in patients with diabetes T. Hisashige, Economic Estimation of Healthcare Service by Disease Management, Report on Research on Health Services 2000 [in Japanese] 2000 Ministry of Health, Labour and Welfare of Japan Tokyo, Japan 91 98
50. H. Hagino, T. Nakamura, S. Fujiwara, M. Oeki, T. Okano, R. Teshima Sequential change in quality of life for patients with incident clinical fractures: a prospective study Osteoporos Int 20 5 2009 695 702
51. R. Garside, M. Pitt, R. Anderson The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation Health Technol Assess 11 18 2007 1 167
52. C. Wanner, V. Krane, W. Marz Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2 2005 238 248
53. G. Eknoyan, G.J. Beck, A.K. Cheung Effect of dialysis dose and membrane flux in maintenance hemodialysis N Engl J Med 347 25 2002 2010 2019
54. J. Cunningham, M. Danese, K. Olson, P. Klassen, G.M. Chertow Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism Kidney Int 68 4 2005 1793 1800
55. G.A. Block, D. Zaun, G. Smits Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients Kidney Int 78 6 2010 578 589
56. G.M. Chertow, L.B. Pupim, G.A. Block Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview Clin J Am Soc Nephrol 2 5 2007 898 905
57. P. Messa, F. Macário, M. Yaqoob The OPTIMA Study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism Clin J Am Soc Nephrol 3 1 2008 36 45
58. S. Fishbane, W.B. Shapiro, D.B. Corry Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE Study results Clin J Am Soc Nephrol 3 6 2008 1718 1725
59. T.I. Shireman, A. Almehmi, J.B. Wetmore, J. Lu, M. Pregenzer, L.D. Quarles Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients Am J Kidney Dis 56 6 2010 1108 1116
60. D.A. Goodkin, J.L. Bragg-Gresham, K.G. Koenig Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS) J Am Soc Nephrol 14 12 2003 3270 3277
61. Guideline Working Group, Japanese Society for Dialysis Therapy Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients Ther Apher Dial 12 6 2008 514 525
62. B. Manns, D. Meltzer, K. Taub, C. Donaldson Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care Health Econ 12 11 2003 949 958